Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial

Marilee Wein for the ACCT Study Group

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monother-apy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH). The study began with a 2-week placebo run-in period (baseline), before which antihypertensive drugs had been discontinued. Amlodipine was then administered at 5-10 mg/ day during a 4-week titration/efficacy period. Patients achieving a goal diastolic blood pressure (DBP) of <90 mm Hg or a decrease in DBP of >10 mm Hg entered a 12-week maintenance phase and had the option to continue long-term therapy thereafter. Echocardiograms were obtained in a subset of patients at the end of the baseline period. In patients with LVH at baseline, echocardiograms were repeated at the end of 16 weeks of therapy (week 18), and at 42 weeks in patients continuing long-term therapy. Thirty-seven percent of 124 hypertensive patients screened for LVH at baseline had LVH detected on echocardiograms. Blacks had a higher incidence of LVH (64%) as compared with whites (34%, p < 0.05). Patients with LVH were more likely to have a higher baseline systolic BP (SBP) and DBP. Their sitting SBP and DBP decreased significantly from a mean of 163/102 mm Hg at baseline to 139/86 mm Hg with amlodipine therapy at week 18 (p < 0.0001). Amlodipine treatment produced a mean decrease of 20-g/m2in LV mass index (p < 0.05) after 16 weeks of treatment and a mean decrease of 43 g/m2in LV mass at week 42 (p < 0.001) as compared with baseline. There were no differences in the degree of LV mass regression between men or women or between older or younger patients; there was a trend toward less regression in blacks (-7 ± 15 g/m2) as compared with whites (-22 ± 9 g/m2) at week 18.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume26
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Amlodipine
Hypertrophy
Blood Pressure
Therapeutics
Calcium Channel Blockers
Left Ventricular Hypertrophy
Antihypertensive Agents
Multicenter Studies
Placebos
Maintenance
Hypertension
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial. / Marilee Wein for the ACCT Study Group.

In: Journal of Cardiovascular Pharmacology, Vol. 26, No. 3, 01.01.1995, p. 471-476.

Research output: Contribution to journalArticle

@article{1d051d55ba1e4749881f040242e0110a,
title = "Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial",
abstract = "As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monother-apy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH). The study began with a 2-week placebo run-in period (baseline), before which antihypertensive drugs had been discontinued. Amlodipine was then administered at 5-10 mg/ day during a 4-week titration/efficacy period. Patients achieving a goal diastolic blood pressure (DBP) of <90 mm Hg or a decrease in DBP of >10 mm Hg entered a 12-week maintenance phase and had the option to continue long-term therapy thereafter. Echocardiograms were obtained in a subset of patients at the end of the baseline period. In patients with LVH at baseline, echocardiograms were repeated at the end of 16 weeks of therapy (week 18), and at 42 weeks in patients continuing long-term therapy. Thirty-seven percent of 124 hypertensive patients screened for LVH at baseline had LVH detected on echocardiograms. Blacks had a higher incidence of LVH (64{\%}) as compared with whites (34{\%}, p < 0.05). Patients with LVH were more likely to have a higher baseline systolic BP (SBP) and DBP. Their sitting SBP and DBP decreased significantly from a mean of 163/102 mm Hg at baseline to 139/86 mm Hg with amlodipine therapy at week 18 (p < 0.0001). Amlodipine treatment produced a mean decrease of 20-g/m2in LV mass index (p < 0.05) after 16 weeks of treatment and a mean decrease of 43 g/m2in LV mass at week 42 (p < 0.001) as compared with baseline. There were no differences in the degree of LV mass regression between men or women or between older or younger patients; there was a trend toward less regression in blacks (-7 ± 15 g/m2) as compared with whites (-22 ± 9 g/m2) at week 18.",
author = "{Marilee Wein for the ACCT Study Group} and Kloner, {Robert A.} and Sowers, {James R.} and DiBona, {Gerald F.} and Michael Gaffney and Marilee Wein and Ralph Alt-house and Anderson, {Kenneth P.} and Appel, {Richard G.} and Applefeld, {Mark M.} and Aronoff, {George R.} and Banas, {John S.} and Bansal, {Vinod K.} and Allan Barker and Barton, {Lewis T.} and Barney Beaver and Joseph Bellomo and Benz, {Joan Ryder} and Bilsker, {Martin S.} and Cheryl Brannon and Braverman, {Gerald L.} and Browne, {Kevin F.} and Hubert Burton and Vincent Canzanello and Caracta, {Antonio R.} and Christos Carvounis and Case, {David B.} and Cronin, {Robert E.} and Cushman, {William C.} and Cutler, {Ralph E.} and William Cushman and Henry DeMots and Dorothy DiNardo-Ekery and DiPette, {Donald J.} and Douglass, {Paul L.} and Douglas Duffy and George Dunea and Clifford Ehrlich and Farag, {Kameel F.} and Ferraro, {James C.} and Forker, {Alan D.} and Forman, {Barry H.} and Linda Francisco and Ga-bris, {Michael P.} and Galichia, {Joseph P.} and Glassberg, {Lawrence E.} and Raymond Graf and Greenspan, {Elliott I.} and Grubb, {Stephen R.} and Haag, {Burritt L.} and Jennifer Hamilton",
year = "1995",
month = "1",
day = "1",
doi = "10.1097/00005344-199509000-00018",
language = "English (US)",
volume = "26",
pages = "471--476",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial

AU - Marilee Wein for the ACCT Study Group

AU - Kloner, Robert A.

AU - Sowers, James R.

AU - DiBona, Gerald F.

AU - Gaffney, Michael

AU - Wein, Marilee

AU - Alt-house, Ralph

AU - Anderson, Kenneth P.

AU - Appel, Richard G.

AU - Applefeld, Mark M.

AU - Aronoff, George R.

AU - Banas, John S.

AU - Bansal, Vinod K.

AU - Barker, Allan

AU - Barton, Lewis T.

AU - Beaver, Barney

AU - Bellomo, Joseph

AU - Benz, Joan Ryder

AU - Bilsker, Martin S.

AU - Brannon, Cheryl

AU - Braverman, Gerald L.

AU - Browne, Kevin F.

AU - Burton, Hubert

AU - Canzanello, Vincent

AU - Caracta, Antonio R.

AU - Carvounis, Christos

AU - Case, David B.

AU - Cronin, Robert E.

AU - Cushman, William C.

AU - Cutler, Ralph E.

AU - Cushman, William

AU - DeMots, Henry

AU - DiNardo-Ekery, Dorothy

AU - DiPette, Donald J.

AU - Douglass, Paul L.

AU - Duffy, Douglas

AU - Dunea, George

AU - Ehrlich, Clifford

AU - Farag, Kameel F.

AU - Ferraro, James C.

AU - Forker, Alan D.

AU - Forman, Barry H.

AU - Francisco, Linda

AU - Ga-bris, Michael P.

AU - Galichia, Joseph P.

AU - Glassberg, Lawrence E.

AU - Graf, Raymond

AU - Greenspan, Elliott I.

AU - Grubb, Stephen R.

AU - Haag, Burritt L.

AU - Hamilton, Jennifer

PY - 1995/1/1

Y1 - 1995/1/1

N2 - As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monother-apy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH). The study began with a 2-week placebo run-in period (baseline), before which antihypertensive drugs had been discontinued. Amlodipine was then administered at 5-10 mg/ day during a 4-week titration/efficacy period. Patients achieving a goal diastolic blood pressure (DBP) of <90 mm Hg or a decrease in DBP of >10 mm Hg entered a 12-week maintenance phase and had the option to continue long-term therapy thereafter. Echocardiograms were obtained in a subset of patients at the end of the baseline period. In patients with LVH at baseline, echocardiograms were repeated at the end of 16 weeks of therapy (week 18), and at 42 weeks in patients continuing long-term therapy. Thirty-seven percent of 124 hypertensive patients screened for LVH at baseline had LVH detected on echocardiograms. Blacks had a higher incidence of LVH (64%) as compared with whites (34%, p < 0.05). Patients with LVH were more likely to have a higher baseline systolic BP (SBP) and DBP. Their sitting SBP and DBP decreased significantly from a mean of 163/102 mm Hg at baseline to 139/86 mm Hg with amlodipine therapy at week 18 (p < 0.0001). Amlodipine treatment produced a mean decrease of 20-g/m2in LV mass index (p < 0.05) after 16 weeks of treatment and a mean decrease of 43 g/m2in LV mass at week 42 (p < 0.001) as compared with baseline. There were no differences in the degree of LV mass regression between men or women or between older or younger patients; there was a trend toward less regression in blacks (-7 ± 15 g/m2) as compared with whites (-22 ± 9 g/m2) at week 18.

AB - As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monother-apy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH). The study began with a 2-week placebo run-in period (baseline), before which antihypertensive drugs had been discontinued. Amlodipine was then administered at 5-10 mg/ day during a 4-week titration/efficacy period. Patients achieving a goal diastolic blood pressure (DBP) of <90 mm Hg or a decrease in DBP of >10 mm Hg entered a 12-week maintenance phase and had the option to continue long-term therapy thereafter. Echocardiograms were obtained in a subset of patients at the end of the baseline period. In patients with LVH at baseline, echocardiograms were repeated at the end of 16 weeks of therapy (week 18), and at 42 weeks in patients continuing long-term therapy. Thirty-seven percent of 124 hypertensive patients screened for LVH at baseline had LVH detected on echocardiograms. Blacks had a higher incidence of LVH (64%) as compared with whites (34%, p < 0.05). Patients with LVH were more likely to have a higher baseline systolic BP (SBP) and DBP. Their sitting SBP and DBP decreased significantly from a mean of 163/102 mm Hg at baseline to 139/86 mm Hg with amlodipine therapy at week 18 (p < 0.0001). Amlodipine treatment produced a mean decrease of 20-g/m2in LV mass index (p < 0.05) after 16 weeks of treatment and a mean decrease of 43 g/m2in LV mass at week 42 (p < 0.001) as compared with baseline. There were no differences in the degree of LV mass regression between men or women or between older or younger patients; there was a trend toward less regression in blacks (-7 ± 15 g/m2) as compared with whites (-22 ± 9 g/m2) at week 18.

UR - http://www.scopus.com/inward/record.url?scp=0029081563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029081563&partnerID=8YFLogxK

U2 - 10.1097/00005344-199509000-00018

DO - 10.1097/00005344-199509000-00018

M3 - Article

C2 - 8583790

AN - SCOPUS:0029081563

VL - 26

SP - 471

EP - 476

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -